Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the USFDA.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals and indicated:
– to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)
– to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.
Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).
𝗖𝗮𝗿𝗲𝗲𝗿 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗮𝘁 𝗦𝘂𝗻𝗿𝗶𝘀𝗲 𝗥𝗲𝗺𝗲𝗱𝗶𝗲𝘀 𝗣𝘃𝘁. 𝗟𝘁𝗱.🚀 We are expanding our team and looking for…
We're Hiring at Synthimed Labs! 🔬 Great Science Begins with Great Minds! At Synthimed Labs,…
WE ARE HIRING | HETERO LABS LIMITED I Location: Baddi, Himachal Pradesh We are looking…
WE ARE HIRING | SYNOKEM LIFESCIENCES PVT. LTD. Synokem Lifesciences Pvt. Ltd., Haridwar, is looking…